Rolf Jan Rutten, Co-founder, CEO
Rolf Jan Rutten has over twenty years experience in general management, product development and business development in the pharmaceutical and biotechnology industry. He held global commercial and operational positions with Akzo Nobel, TNO and Clinquest group. He also co-founded thromboDx, a molecular diagnostics company (sold to Illumina) and Dybly AG, a Basel-based cardiovascular company.
Helmuth van Es, Co-founder, CSO
Dr. Helmuth van Es has been responsible for the creation of a number of biotechnology companies. He is co-founder of Galapagos where he has held various R & D positions including Head of Science at Galapagos where he and his team developed a powerful target discovery and validation RNAi platform and applied this to a range of disease areas such as allergy, osteoporosis, osteoarthritis, rheumatoid arthritis, Alzheimer and cystic fibrosis. His track-record includes international drug discovery and development management of start-up and mid-sized companies. He currently serves on the board of Antabio an antibacterial drug development company and Hifibio an MIT, Broad, Harvard and ESPCI microfluidics spinout focussing on the development of therapeutic antibodies. In 2015 he co-founded Citryll an antibody drug development company targeting neutrophil extracellular traps (NETosis) for treatment of SLE, RA and other diseases. He received his PhD in medicine from the University of Amsterdam and did postdoctoral research at McGill University in Montréal.
Albert Edge, Scientific c0-founder, Consultant
Dr. Albert Edge is on the faculty of Harvard Medical School and investigator at Massachusetts Eye and Ear Infirmary. He was previously an Assistant Professor at Harvard Medical School and the Joslin Diabetes Center and in 2003 took his current position at MEEI. He works on stem cell differentiation and regeneration of the inner ear and has identified developmental pathways that are effective in converting stem cells into cochlear hair cells and neurons. Prior to his current position, Dr. Edge was at Diacrin where he was Senior Director of Cell and Molecular Biology and at Dyax where he was Vice President of Discovery Research. He received his Ph.D. in biochemistry from Albany Medical College and was Postdoctoral Fellow in the Department of Biological Chemistry at Harvard Medical School.